Form 4: Avalo Therapeutics Insider Trades Common Stock

Mittie Doyle, Chief Medical Officer at Avalo Therapeutics, Inc., reported transactions involving common stock and stock options on June 23, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, Inc., engaged in stock transactions on June 23, 2026.
• These transactions included the acquisition of 1,450 shares of common stock at $8.04 per share and the disposal of 1,450 shares of common stock at $18 per share.
• The acquisition was made pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025.
• Following these transactions, Doyle beneficially owns 51,776 shares of common stock directly.
• Additionally, Doyle holds a stock option to buy 1,450 shares of common stock at an exercise price of $8.04, with vesting commencing January 28, 2026, and continuing over three years.
• The total number of derivative securities beneficially owned by Doyle is 116,871.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It details routine insider transactions under a pre-established plan, without providing new strategic or financial information that would significantly alter the investment outlook.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and pre-determined approach to stock transactions, which can reduce concerns about insider trading.
• The acquisition of shares at a lower price ($8.04) while disposing of shares at a higher price ($18) could be interpreted positively, though the net effect depends on the total number of shares held and the individual's investment strategy.
• The continued vesting of stock options over three years suggests a commitment to continued service and potential future value realization for the executive.

Negatives

• The disposal of 1,450 shares at a significantly higher price ($18) compared to the acquisition price ($8.04) might indicate a belief that the stock price has reached a favorable point for selling, or a need to diversify holdings.
• The filing does not provide context on the overall financial health or recent performance of Avalo Therapeutics, making it difficult to assess the broader implications of these insider trades.

Risks

• The Rule 10b5-1 plan is subject to market conditions and the company's performance, which could impact the value of the acquired shares and vested options.
• Future vesting of stock options is contingent upon continued service, meaning any departure from the company would affect the realization of this compensation.

Future Outlook

The stock option held by Mittie Doyle has a vesting schedule that extends over three years from January 28, 2026, contingent on continued service. This indicates a forward-looking incentive tied to ongoing employment.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by an executive at a biotechnology company like Avalo Therapeutics is common practice to manage personal stock sales and purchases in a compliant manner, especially given the inherent volatility in the sector.

Stakeholder Impact

• Shareholders: The disposal of shares by an executive might be interpreted by some shareholders as a signal, though the Rule 10b5-1 plan mitigates this concern. The acquisition of shares at a lower price could be seen as a positive sign of executive confidence in future stock appreciation.
• Employees: The stock option vesting schedule reinforces the importance of continued employment for executive compensation realization.
• Management: The filing confirms adherence to regulatory requirements for reporting insider transactions.

Next Steps

• Continued vesting of stock options over the next three years, subject to continued employment.
• Potential future transactions under the Rule 10b5-1 plan, depending on its terms and market conditions.

Key Dates

Keywords

Avalo Therapeutics, AVTX, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Beneficial Ownership, Common Stock, Executive Compensation, SEC Filing